Last reviewed · How we verify

low dose clonidine HCl sustained release

Addrenex Pharmaceuticals, Inc. · Phase 3 active Small molecule

Clonidine HCl works by stimulating alpha-2 adrenergic receptors in the brain, which decreases sympathetic nervous system activity and lowers blood pressure.

Clonidine HCl works by stimulating alpha-2 adrenergic receptors in the brain, which decreases sympathetic nervous system activity and lowers blood pressure. Used for Hypertension.

At a glance

Generic namelow dose clonidine HCl sustained release
SponsorAddrenex Pharmaceuticals, Inc.
Drug classCentral alpha-2 adrenergic agonist
TargetAlpha-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

This results in decreased peripheral vascular resistance and heart rate, leading to a decrease in blood pressure. Clonidine HCl also has a sedative effect, which can be beneficial in treating hypertension.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: